Mnkd Stocktwits Subscriptions

Track mannkind corp (mnkd) stock price, quote, latest community messages, chart, news and other stock related information. Despite the reduction in stake, retail is enthusiastic about tyvaso’s impact on mannkind’s third quarter earnings scheduled for nov. Share your ideas and get valuable insights from the community of like minded traders and investors.

MNKD Mannkind Corp Stock Price Forecast 2025, 2026, 2030 to 2050

Stocktwits is a platform for investors to share and discuss stock market news and opinions. This transaction suggested that mannkind's remaining stake was valued at approximately $1.8 billion. Find the latest news and sentiment on mnkd, a biotechnology company that develops inhaled insulin and other drugs, from various sources and media outlets.

• 28 Liberty Street

Find the latest mannkind corporation (mnkd) stock quote, history, news and other vital information to help you with your stock trading and investing.

Is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Get the latest price, performance, and news of mannkind corp. (mnkd), a biotech company developing inhaled therapeutic products. See analyst ratings, recent events, and historical data on marketwatch.

Join the conversation about mnkd stock in yahoo finance's community. Share your opinion and gain insight from other traders and investors on the latest news and trends. Join the investorshub community to share your ideas and access live updates on mannkind corp (mnkd), a biotech company developing inhaled insulin products. See the latest news, presentations, and data from recent studies of afrezza in adults and pediatrics.

Find the latest mannkind corporation (mnkd) stock discussion in yahoo finance's forum.

Share your opinion and gain insight from other stock traders and investors. The latest messages and market ideas from nate pile (@natesnotes) on stocktwits. Helping main street beat wall street since 1995 (i can be reached at nate(at)natesnotes(dot)com if you have any questions) Checkout mannkind corp (mnkd) earnings results, eps expectations and actual eps values for both quarterly and annual periods.

Discover whether mnkd beat the street expectations or not? Get all financial information for mannkind corp (mnkd) including market capitalization, pe ratio, ebitda, eps, previous close and open price, 52 week high & 52 week low, beta and much more Mannkind develops inhaled therapeutics and devices for people with endocrine and lung diseases. Find the latest mannkind corp.

(mnkd) discussion and analysis from ihub's community of investors.

Mannkind corporation to hold 2024 fourth quarter and full year financial results conference call on february 26, 2025. And westlake village, calif., feb. The latest messages and market ideas from mnkd (@mnkd1) on stocktwits. The largest community for investors and traders

Interactive chart for mannkind corporation (mnkd), analyze all the data with a huge range of indicators. Find the latest mannkind corporation (mnkd) stock quote, history, news and other vital information to help you with your stock trading and investing. Track teladoc health inc (tdoc) stock price, quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

The latest messages and market ideas from mat jungssi (@mnkd) on stocktwits.

The largest community for investors and traders Is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Mannkind reported q4 revenue of $76.8 million, surpassing analyst expectations of $74.4 million. Earnings per share (eps) came in at $0.03, slightly below the consensus estimate of $0.04.

Michael castagna, ceo of mannkind, expressed optimism about the development, stating: Mannkind (mnkd) appears an attractive pick, as it has been recently upgraded to a zacks rank #1 (strong buy).